NasdaqGM - Nasdaq Real Time Price • USD
Xenon Pharmaceuticals Inc. (XENE)
As of 10:11 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 17 | 17 |
| Avg. Estimate | -0.66 | -0.7 | -2.91 | -3.29 |
| Low Estimate | -0.77 | -0.82 | -3.54 | -4.47 |
| High Estimate | -0.56 | -0.58 | -2.35 | -1.11 |
| Year Ago EPS | -0.63 | -0.72 | -2.73 | -2.91 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 17 | 17 |
| Avg. Estimate | -- | -- | 2.39M | 5.64M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 25M | 70.22M |
| Year Ago Sales | -- | -- | -- | 2.39M |
| Sales Growth (year/est) | -- | -- | -- | 136.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.62 | -0.7 | -0.77 | -0.76 |
| EPS Actual | -0.63 | -0.72 | -0.73 | -0.64 |
| Difference | -0.01 | -0.02 | 0.04 | 0.12 |
| Surprise % | -1.60% | -2.90% | 5.20% | 15.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.66 | -0.7 | -2.91 | -3.29 |
| 7 Days Ago | -0.66 | -0.7 | -2.91 | -3.29 |
| 30 Days Ago | -0.66 | -0.7 | -2.91 | -3.28 |
| 60 Days Ago | -0.76 | -0.79 | -3.28 | -3.68 |
| 90 Days Ago | -0.76 | -0.79 | -3.28 | -3.68 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | XENE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -4.80% | -- | -- | 0.30% |
| Next Qtr. | 2.80% | -- | -- | 9.80% |
| Current Year | -6.60% | -- | -- | 4.50% |
| Next Year | -13.10% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 8.90% | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/12/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/10/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 3/1/2024 |
| Maintains | Wedbush: Outperform to Outperform | 3/1/2024 |
| Maintains | Needham: Buy to Buy | 3/1/2024 |
| Initiated | Citigroup: Buy | 1/4/2024 |
Related Tickers
SNDX Syndax Pharmaceuticals, Inc.
20.94
-0.14%
CYTK Cytokinetics, Incorporated
66.60
+1.56%
XNCR Xencor, Inc.
18.31
-0.33%
KRYS Krystal Biotech, Inc.
164.82
+1.72%
EWTX Edgewise Therapeutics, Inc.
15.64
-0.06%
CRNX Crinetics Pharmaceuticals, Inc.
44.52
+0.68%
ENTA Enanta Pharmaceuticals, Inc.
12.92
-1.75%
LBPH Longboard Pharmaceuticals, Inc.
20.64
+1.83%
ELVN Enliven Therapeutics, Inc.
17.39
+0.09%
KALV KalVista Pharmaceuticals, Inc.
11.02
-1.74%